Davita (DVA) Stock News

Blue Cross and Blue Shield of Minnesota has launched a new value-based kidney care program in partnership with VillageHealth, a subsidiary of DaVita. This initiative aims to enhance health outcomes and reduce care costs for members with chronic kidney disease (CKD) and end-stage kidney disease (ESKD). Key elements include coordinated care, early patient outreach, predictive analytics for high-risk individuals, and comprehensive patient education. The program seeks to delay disease progression and improve quality of life for thousands while aiming to decrease hospital admissions by nearly 30%.

DaVita has released its inaugural Diversity & Belonging (D&B) report, outlining its metrics and commitments to fostering a diverse workplace. CEO Javier Rodriguez emphasizes the importance of diversity in enhancing workplace culture and patient connections. The company expanded its D&B program to include health equity and economic mobility in 2020. DaVita aims to create an inclusive environment supporting all individuals, seeking to unlock their full potential. As of December 31, 2020, DaVita served over 204,200 patients through 2,816 outpatient dialysis centers across the U.S.

On March 25, 2021, the Biden administration announced a partnership with dialysis providers, including DaVita, to facilitate COVID-19 vaccinations for dialysis patients and staff. Javier Rodriguez, CEO of DaVita, praised the initiative, emphasizing its importance for high-risk patients and health equity. The program aims to provide vaccines at outpatient dialysis centers, thereby enhancing access and reducing vaccine hesitancy. DaVita, a leader in kidney care services, operates numerous centers across the U.S. and globally, dedicated to improving patient care and outcomes.

On March 23, 2021, Fresenius Medical Care North America (FMCNA) and DaVita Kidney Care announced a collaboration to enhance home dialysis services for patients in the U.S. The partnership includes the provision of NxStage home hemodialysis machines and related technologies to promote home treatment options. This initiative aims to improve quality of life for patients with chronic kidney failure by facilitating greater autonomy in their care. The NxStage systems offer innovative connectivity features to track treatment, aligning with recent Medicare programs to boost home dialysis adoption.

NephroSant has successfully closed a $16 million Series A funding round, led by DaVita Venture Group with participation from DigitalDx Ventures and others. This funding will support the launch of Qsant™, a non-invasive urine test for detecting kidney transplant rejection. Current rejection rates stand at 40%. Qsant™ simplifies the testing process by using a single urine sample, enhancing patient convenience and safety, especially amid the COVID-19 pandemic. The investment highlights the commitment to improve kidney health and patient outcomes.

DaVita Inc. (NYSE: DVA) will participate in the 2021 Barclays Global Healthcare Conference, with CFO Joel Ackerman addressing questions in a virtual fireside chat on March 10, 2021, at 4:10 p.m. Eastern Time. A live audio webcast will be accessible via DaVita's investor website, with a replay available for 90 days. DaVita is a leading kidney care provider, serving over 204,200 patients across 2,816 outpatient dialysis centers in the U.S. and operating internationally. The company focuses on improving patient care and reducing hospitalizations.

DaVita Inc. (NYSE: DVA) has announced the upsize of its private offering of senior notes from $750 million to $1 billion. These 4.625% notes are due on June 1, 2030 and will be issued at an offering price of 101.750%. The closing of the offering is expected on February 26, 2021. Proceeds will be used to pay down $550 million in revolving credit, cover offering expenses, and support general corporate purposes. The offering is targeted at qualified institutional buyers under Regulation S.

DaVita Inc. (NYSE: DVA) has initiated a private offering of $750 million in additional 4.625% senior notes, maturing on June 1, 2030. These notes will be issued under an existing indenture and will share the same terms as previously issued notes of $1.75 billion. Proceeds will be used to reduce borrowings, cover offering expenses, and for general corporate purposes, including potential stock repurchases. This issuance is targeting qualified institutional buyers and is subject to regulatory compliance.

DaVita reported financial results for Q4 and full-year 2020, with diluted EPS from continuing operations at $6.39, a 38.9% increase year-over-year. Q4 diluted EPS was $1.67, impacted by COVID-19 with a $60 million operating income loss. Total revenues were $2.905 billion for Q4 and $11.551 billion for the year. Operating cash flow was $485 million in Q4, and free cash flow was $210 million. The company served approximately 240,400 patients across 3,137 centers, opening 14 new centers in Q4.